Clinical TrialJun 1, 2026, 09:01 AM
Oncolytics' Pelareorep + RAS Inhibitors Show Enhanced Anti-Tumor Activity
AI Summary
Oncolytics Biotech announced initial preclinical data showing its investigational immunotherapy, pelareorep, combined with RAS inhibitor modalities, demonstrated greater anti-tumor activity in solid tumor models than individual approaches. These findings support pelareorep's role as an immune-priming backbone for next-generation targeted therapies, particularly for difficult-to-treat RAS-mutated pancreatic and colorectal cancers. The company plans further studies to evaluate immune activation, tumor response durability, and time-to-resistance, with full results expected in late 2026.
Key Highlights
- Pelareorep combined with RAS inhibitors showed greater anti-tumor activity in solid tumor models.
- Initial preclinical data supports pelareorep as an immune-priming backbone for targeted therapies.
- Oncolytics plans additional studies in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).
- Future studies will evaluate immune activation, tumor response durability, and time-to-resistance.
- Full results from initial preclinical studies are expected in fall or winter of 2026.
- Pelareorep has FDA Fast Track designation for colorectal and pancreatic cancer.
Price Impact
More from ONCY